In recent years, new and innovative immunotherapy drugs entered the market
revolutionizing the clinical management of patients suffering of cancer diseases. These …

3038 Background: Biomarkers to predict the efficacy of immunotherapy have been awaited.
A phase II study of five therapeutic epitope-peptides with oxaliplatin-based chemotherapy as …

We here explore the soluble Human Leukocyte Antigen-G (sHLA-G) expression level as
clinical biomarker in metastatic colorectal cancer (mCRC). To this aim the sHLA-G protein …

245 Background: HLA-E is an MHC Class I antigen which inhibits NK cell activity by binding
to CD94 receptor. Overexpression of HLA-E on crc cells is associated with poor prognostic …

Identifying innovative molecules involved in the tumor immune escape process could help
refine the survival stratification of colorectal cancer (CRC) patients. HLA-G, a non-classical …

Microenvironmental factors such as non-classical human leukocyte antigen-G (HLA-G) have
been associated with cancer invasiveness and metastatic progression. HLA-G expression …

Immune checkpoint inhibitors (ICIs) have become a promising area of research for cancer
treatment. In addition to the well-known ICIs targeting PD-1/PD-L1, HLA-G/ILT-2/-4 is …

e14507 Background: Biomarkers to predict the efficacy of immunotherapy have been
awaited. A phase I/II study of five therapeutic epitope-peptides for advanced colorectal …

Colorectal cancer (CRC) is one of the most diffuse cancers worldwide and is still a clinical
burden. Increasing evidences associate CRC clinical outcome to immune contexture …

T cell-mediated immune therapies have emerged as a promising treatment modality in
different malignancies including colorectal cancer (CRC). However, only a fraction of …